本文選題：無定型固體分散體 + 生物利用度��； 參考：《中國新藥雜志》2017年04期

【摘要】：無定型藥物活性成分(active pharmaceutical ingredients,APIs)比晶型APIs具有更高的表觀溶解度,但其熱穩(wěn)定性極差,貯藏中易轉(zhuǎn)變?yōu)榉�(wěn)定的結(jié)晶型。將晶型APIs無定型化,制備成無定型固體分散體(amorphous solid dispersion,ASD),使無定型APIs長期穩(wěn)定,為藥物制劑開發(fā)尤其是BCS(biopharmaceutical classification system,BCS)Ⅱ類或Ⅳ類的難溶性APIs制劑的開發(fā),提供了一種新方法。本文主要對無定型態(tài)的APIs熱力學(xué)特征,制備無定型固體分散體的制備技術(shù)及載體進(jìn)行綜述,其中對新型納米無機(jī)載體和適用于工業(yè)化生產(chǎn)的無定型固體分散體制備技術(shù)進(jìn)行詳細(xì)敘述和評價(jià)。
[Abstract]:The active pharmaceutical redientsapis) has a higher apparent solubility than crystalline APIs, but its thermal stability is extremely poor, and it is easy to change into a stable crystalline type in storage. Amorphous solid dispersion was prepared from amorphous APIs by astyping, which made the amorphous APIs stable for a long time. It provided a new method for the development of drug preparation, especially for the development of insoluble APIs preparation of class 鈪，

本文編號：1802790